Sign In
Buy HROW
$33.32
+0.460 (+1.40%)
At Close: Jun 03, 2026
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
07:00am, Wednesday, 05'th Jun 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (O
Harrow to Present at Two Investor Conferences in May
07:00am, Wednesday, 15'th May 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
10:48am, Tuesday, 14'th May 2024
Harrow, Inc. (NASDAQ:HROW ) Q1 2024 Earnings Call Transcript May 14, 2024 8:00 AM ET Company Participants Jamie Webb - Director of Communications and IR Mark L. Baum - CEO Andrew Boll - CFO Conference
Harrow Announces First Quarter 2024 Financial Results
04:01pm, Monday, 13'th May 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company a
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
07:00am, Monday, 13'th May 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, H
Harrow: Merits A Buy On Sales Potential
12:20pm, Thursday, 02'nd May 2024
Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is expect
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
04:42am, Thursday, 02'nd May 2024
Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has cripp
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
07:00am, Thursday, 25'th Apr 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ende
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
08:16am, Tuesday, 02'nd Apr 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completio
Why Is Harrow (HROW) Stock Up 5% Today?
08:34am, Wednesday, 20'th Mar 2024
Harrow (NASDAQ: HROW ) stock is moving on Wednesday following the release of the eyecare pharmaceutical company's earnings report for Q4 2023. The Harrow report starts with core earnings per share o
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
05:45pm, Tuesday, 19'th Mar 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Compan
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
07:00am, Tuesday, 05'th Mar 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth q
Harrow's Drug Iheezo Is Off To A Great Start
09:30am, Monday, 19'th Feb 2024
Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheez
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
04:01pm, Thursday, 15'th Feb 2024
NASHVILLE, Tenn. & TORONTO--(BUSINESS WIRE)---- $HROW--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada's largest pharmaceutical compa
